Stockscreener 앱 받기
83.46
6.95%
5.42
시간 외 거래:
83.82
0.36
+0.43%
전일 마감가:
$78.04
열려 있는:
$79.51
하루 거래량:
311.24K
Relative Volume:
1.90
시가총액:
$649.92M
수익:
-
순이익/손실:
$-4.98M
주가수익비율:
-63.34
EPS:
-1.3177
순현금흐름:
$-3.85M
1주 성능:
+1.63%
1개월 성능:
+18.00%
6개월 성능:
+197.97%
1년 성능:
+103.02%
1일 변동 폭
$76.00
$84.58
1주일 범위
$75.11
$84.58
52주 변동 폭
$23.18
$97.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
83.46 | 607.71M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences (DRUG) Expected to Announce Quarterly Earnings on Monday - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase – Time to Buy? - Defense World
How Bright Minds Biosciences Inc. stock performs in high volatility marketsDividend Stability Analysis & Superior Trading Ideas - bollywoodhelpline.com
Bright Minds Biosciences (DRUG) Projected to Post Earnings on Monday - MarketBeat
DRUG: R&D-driven net loss rose to $12.2M; $82.9M cash secures 12+ months' runway amid ongoing clinical trials - TradingView — Track All Markets
Will Bright Minds Biosciences Inc. stock reach Wall Street targetsLayoff News & Low Drawdown Trading Strategies - Улправда
How institutional buying supports Bright Minds Biosciences Inc. stock2025 Market Sentiment & Stock Market Timing Techniques - Улправда
Why Bright Minds Biosciences Inc. stock is popular among millennials2025 Market Overview & Weekly High Return Stock Forecasts - Улправда
TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 By Investing.com - Investing.com Canada
Will Bright Minds Biosciences Inc. stock deliver shareholder valueMarket Performance Summary & Risk Controlled Stock Pick Alerts - Улправда
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 5.4%Here's What Happened - MarketBeat
Bullish Divergence Spotted in Tulsyan NEC Limited MomentumDividend Yield Trends & Fast Growing Investment Plans - earlytimes.in
Bright Minds Biosciences Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Tools to Monitor Market Corrections - earlytimes.in
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 52-Week HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.3%Here's Why - MarketBeat
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials - Proactive financial news
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 1-Year HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Sets New 52-Week HighStill a Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 10.3%Time to Buy? - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
What drives Bright Minds Biosciences Inc stock priceEnergy Sector Updates & High Yield Trading Signals - earlytimes.in
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year HighHere's Why - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Cut to Hold at Zacks Research - Defense World
Why Bright Minds Biosciences Inc. stock attracts high net worth investorsPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
Cantor Fitzgerald Analysts Lower Earnings Estimates for DRUG - MarketBeat
An Intrinsic Calculation For Bright Minds Biosciences Inc. (CSE:DRUG) Suggests It's 44% Undervalued - simplywall.st
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
(DRUG) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.2%Still a Buy? - MarketBeat
What technical signals suggest for Bright Minds Biosciences Inc. stockJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why - MSN
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock - Investing.com Nigeria
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $81.00 - Defense World
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):